On the 4th, microbiological testing company Creative life science CO., LTD. announced the recent completion of a NT$204 million cash increase, introducing strategic investors, including Bora Pharmaceuticals, Onyx Healthcare, and BioLASCO Taiwan, all listed biopharmaceutical companies. The company has also outlined plans for a public offering and listing on the Taiwan Stock Exchange in 2025.
Dr. Yueh-Ting Tsai, General Manager of Creative life science, expressed expectations for the successful introduction of strategic investors with international success experience and further integration of industrial resources. Over the next three years, Creative life science will invest NT$300 million to expand its PIC/S GMP-grade cell culture-based manufacturing plant at the Hsinchu Biomedical Science Park. The objective is to provide international cell culture-based CDMO and CRO contract research services, aiming to establish a complete cell therapy and CDMO supply chain in Taiwan that can swiftly comply with international regulations. This initiative is aimed at assisting emerging biotech companies in Taiwan in strengthening their product competitiveness.
With over 45 years of deep involvement in the domestic biopharmaceutical industry, Creative life science has played multiple roles in research and development, manufacturing, and distribution across three major areas: biomedicine, food safety, and clinical infectious diseases. Its proprietary brand CMP has developed over 600 reagents and has seen successful exportation to countries such as Singapore, Hong Kong, Canada, Malaysia, Vietnam, and the Philippines in recent years.
As the development of Advanced Therapy Medicinal Products (ATMPs) accelerates, the demand for related testing reagents and contract testing services is on the rise. However, many biopharmaceutical companies in Taiwan currently rely on foreign suppliers, resulting in challenges in controlling product development and market launch schedules. Thus, Creative life science's vision is to establish a complete biopharmaceutical supply chain and become the top partner for Taiwanese manufacturers.
Among the strategic investors, Bora Pharmaceuticals stands out as the largest professional CDMO manufacturer in the Taiwanese pharmaceutical industry, boasting numerous successful international mergers and strategic cooperation experiences. It is also one of the few pharmaceutical companies in Asia with international production and supply chain management capabilities, along with international market channel advantages.
Onyx Healthcare is a leading global supplier of medical-grade information detection equipment, with extensive experience in the European and American medical equipment markets and a steadily growing market share. Currently, it serves as the primary partner for international giants such as Intel and NVIDIA to venture into the medical AI field.
BioLASCO Taiwan, in collaboration with the world's largest experimental animal supply company, Charles River Lab., has established Taiwan's first SPF (Specific Pathogen-Free) experimental animal center meeting international standards. In recent years, it has actively expanded into international markets such as mainland China, India, and Southeast Asia.
Creative life science will leverage strategic investors to connect and integrate upstream and downstream industry resources. In addition to providing more comprehensive product development solutions for Taiwanese biopharmaceutical companies, it will further penetrate the international market, positioning Taiwan as an indispensable biopharmaceutical supply chain hub in the Asia-Pacific region.
